Liposomal Drug-delivery System is a pharmaceutical technology that encapsulates drugs within lipid-based vesicles called liposomes. These microscopic structures enhance the delivery of drugs to target tissues, improve drug stability, and control drug release rates. Liposomal drug delivery is used to enhance the therapeutic effects of medications, reduce side effects, and improve the solubility of poorly water-soluble drugs.
The global market for Liposomal Drug-delivery System was estimated to be worth US$ 3328 million in 2023 and is forecast to a readjusted size of US$ 6503.3 million by 2030 with a CAGR of 10.1% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Liposomal Drug-delivery System, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Liposomal Drug-delivery System by region & country, by Type, and by Application.
The Liposomal Drug-delivery System market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Drug-delivery System.
Market Segmentation
By Company
Lipoid Kosmetik
Lucas Meyer Cosmetics
Nippon Fine Chemical
Enoc Solutions
Nanovec
Lipotec
Croda
H&A Pharmachem
Lipomize
ID bio
BioSpectrum
Derma Clinical
Kewpie Corporation
Nanohealth Biotech
Creative Biostructure
Phenbiox
NOF CORPORATION
KYOWA PHARMA CHEMICAL
Nikko Chemicals
Segment by Type:
Liposome Vitamin
Liposome Ceramide
Liposome CoQ10
Others
Segment by Application
Medical
Cosmetics
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Liposomal Drug-delivery System manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Liposomal Drug-delivery System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Liposomal Drug-delivery System in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Liposomal Drug-delivery System Product Introduction
1.2 Global Liposomal Drug-delivery System Market Size Forecast
1.3 Liposomal Drug-delivery System Market Trends & Drivers
1.3.1 Liposomal Drug-delivery System Industry Trends
1.3.2 Liposomal Drug-delivery System Market Drivers & Opportunity
1.3.3 Liposomal Drug-delivery System Market Challenges
1.3.4 Liposomal Drug-delivery System Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Liposomal Drug-delivery System Players Revenue Ranking (2023)
2.2 Global Liposomal Drug-delivery System Revenue by Company (2019-2024)
2.3 Key Companies Liposomal Drug-delivery System Manufacturing Base Distribution and Headquarters
2.4 Key Companies Liposomal Drug-delivery System Product Offered
2.5 Key Companies Time to Begin Mass Production of Liposomal Drug-delivery System
2.6 Liposomal Drug-delivery System Market Competitive Analysis
2.6.1 Liposomal Drug-delivery System Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Liposomal Drug-delivery System Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Drug-delivery System as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Liposome Vitamin
3.1.2 Liposome Ceramide
3.1.3 Liposome CoQ10
3.1.4 Others
3.2 Global Liposomal Drug-delivery System Sales Value by Type
3.2.1 Global Liposomal Drug-delivery System Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Liposomal Drug-delivery System Sales Value, by Type (2019-2030)
3.2.3 Global Liposomal Drug-delivery System Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Medical
4.1.2 Cosmetics
4.2 Global Liposomal Drug-delivery System Sales Value by Application
4.2.1 Global Liposomal Drug-delivery System Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Liposomal Drug-delivery System Sales Value, by Application (2019-2030)
4.2.3 Global Liposomal Drug-delivery System Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Liposomal Drug-delivery System Sales Value by Region
5.1.1 Global Liposomal Drug-delivery System Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Liposomal Drug-delivery System Sales Value by Region (2019-2024)
5.1.3 Global Liposomal Drug-delivery System Sales Value by Region (2025-2030)
5.1.4 Global Liposomal Drug-delivery System Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Liposomal Drug-delivery System Sales Value, 2019-2030
5.2.2 North America Liposomal Drug-delivery System Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Liposomal Drug-delivery System Sales Value, 2019-2030
5.3.2 Europe Liposomal Drug-delivery System Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Liposomal Drug-delivery System Sales Value, 2019-2030
5.4.2 Asia Pacific Liposomal Drug-delivery System Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Liposomal Drug-delivery System Sales Value, 2019-2030
5.5.2 South America Liposomal Drug-delivery System Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Liposomal Drug-delivery System Sales Value, 2019-2030
5.6.2 Middle East & Africa Liposomal Drug-delivery System Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Liposomal Drug-delivery System Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Liposomal Drug-delivery System Sales Value
6.3 United States
6.3.1 United States Liposomal Drug-delivery System Sales Value, 2019-2030
6.3.2 United States Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Liposomal Drug-delivery System Sales Value, 2019-2030
6.4.2 Europe Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Liposomal Drug-delivery System Sales Value, 2019-2030
6.5.2 China Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.5.3 China Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Liposomal Drug-delivery System Sales Value, 2019-2030
6.6.2 Japan Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Liposomal Drug-delivery System Sales Value, 2019-2030
6.7.2 South Korea Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Liposomal Drug-delivery System Sales Value, 2019-2030
6.8.2 Southeast Asia Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Liposomal Drug-delivery System Sales Value, 2019-2030
6.9.2 India Liposomal Drug-delivery System Sales Value by Type (%), 2023 VS 2030
6.9.3 India Liposomal Drug-delivery System Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Lipoid Kosmetik
7.1.1 Lipoid Kosmetik Profile
7.1.2 Lipoid Kosmetik Main Business
7.1.3 Lipoid Kosmetik Liposomal Drug-delivery System Products, Services and Solutions
7.1.4 Lipoid Kosmetik Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.1.5 Lipoid Kosmetik Recent Developments
7.2 Lucas Meyer Cosmetics
7.2.1 Lucas Meyer Cosmetics Profile
7.2.2 Lucas Meyer Cosmetics Main Business
7.2.3 Lucas Meyer Cosmetics Liposomal Drug-delivery System Products, Services and Solutions
7.2.4 Lucas Meyer Cosmetics Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.2.5 Lucas Meyer Cosmetics Recent Developments
7.3 Nippon Fine Chemical
7.3.1 Nippon Fine Chemical Profile
7.3.2 Nippon Fine Chemical Main Business
7.3.3 Nippon Fine Chemical Liposomal Drug-delivery System Products, Services and Solutions
7.3.4 Nippon Fine Chemical Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.3.5 Enoc Solutions Recent Developments
7.4 Enoc Solutions
7.4.1 Enoc Solutions Profile
7.4.2 Enoc Solutions Main Business
7.4.3 Enoc Solutions Liposomal Drug-delivery System Products, Services and Solutions
7.4.4 Enoc Solutions Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.4.5 Enoc Solutions Recent Developments
7.5 Nanovec
7.5.1 Nanovec Profile
7.5.2 Nanovec Main Business
7.5.3 Nanovec Liposomal Drug-delivery System Products, Services and Solutions
7.5.4 Nanovec Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.5.5 Nanovec Recent Developments
7.6 Lipotec
7.6.1 Lipotec Profile
7.6.2 Lipotec Main Business
7.6.3 Lipotec Liposomal Drug-delivery System Products, Services and Solutions
7.6.4 Lipotec Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.6.5 Lipotec Recent Developments
7.7 Croda
7.7.1 Croda Profile
7.7.2 Croda Main Business
7.7.3 Croda Liposomal Drug-delivery System Products, Services and Solutions
7.7.4 Croda Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.7.5 Croda Recent Developments
7.8 H&A Pharmachem
7.8.1 H&A Pharmachem Profile
7.8.2 H&A Pharmachem Main Business
7.8.3 H&A Pharmachem Liposomal Drug-delivery System Products, Services and Solutions
7.8.4 H&A Pharmachem Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.8.5 H&A Pharmachem Recent Developments
7.9 Lipomize
7.9.1 Lipomize Profile
7.9.2 Lipomize Main Business
7.9.3 Lipomize Liposomal Drug-delivery System Products, Services and Solutions
7.9.4 Lipomize Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.9.5 Lipomize Recent Developments
7.10 ID bio
7.10.1 ID bio Profile
7.10.2 ID bio Main Business
7.10.3 ID bio Liposomal Drug-delivery System Products, Services and Solutions
7.10.4 ID bio Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.10.5 ID bio Recent Developments
7.11 BioSpectrum
7.11.1 BioSpectrum Profile
7.11.2 BioSpectrum Main Business
7.11.3 BioSpectrum Liposomal Drug-delivery System Products, Services and Solutions
7.11.4 BioSpectrum Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.11.5 BioSpectrum Recent Developments
7.12 Derma Clinical
7.12.1 Derma Clinical Profile
7.12.2 Derma Clinical Main Business
7.12.3 Derma Clinical Liposomal Drug-delivery System Products, Services and Solutions
7.12.4 Derma Clinical Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.12.5 Derma Clinical Recent Developments
7.13 Kewpie Corporation
7.13.1 Kewpie Corporation Profile
7.13.2 Kewpie Corporation Main Business
7.13.3 Kewpie Corporation Liposomal Drug-delivery System Products, Services and Solutions
7.13.4 Kewpie Corporation Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.13.5 Kewpie Corporation Recent Developments
7.14 Nanohealth Biotech
7.14.1 Nanohealth Biotech Profile
7.14.2 Nanohealth Biotech Main Business
7.14.3 Nanohealth Biotech Liposomal Drug-delivery System Products, Services and Solutions
7.14.4 Nanohealth Biotech Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.14.5 Nanohealth Biotech Recent Developments
7.15 Creative Biostructure
7.15.1 Creative Biostructure Profile
7.15.2 Creative Biostructure Main Business
7.15.3 Creative Biostructure Liposomal Drug-delivery System Products, Services and Solutions
7.15.4 Creative Biostructure Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.15.5 Creative Biostructure Recent Developments
7.16 Phenbiox
7.16.1 Phenbiox Profile
7.16.2 Phenbiox Main Business
7.16.3 Phenbiox Liposomal Drug-delivery System Products, Services and Solutions
7.16.4 Phenbiox Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.16.5 Phenbiox Recent Developments
7.17 NOF CORPORATION
7.17.1 NOF CORPORATION Profile
7.17.2 NOF CORPORATION Main Business
7.17.3 NOF CORPORATION Liposomal Drug-delivery System Products, Services and Solutions
7.17.4 NOF CORPORATION Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.17.5 NOF CORPORATION Recent Developments
7.18 KYOWA PHARMA CHEMICAL
7.18.1 KYOWA PHARMA CHEMICAL Profile
7.18.2 KYOWA PHARMA CHEMICAL Main Business
7.18.3 KYOWA PHARMA CHEMICAL Liposomal Drug-delivery System Products, Services and Solutions
7.18.4 KYOWA PHARMA CHEMICAL Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.18.5 KYOWA PHARMA CHEMICAL Recent Developments
7.19 Nikko Chemicals
7.19.1 Nikko Chemicals Profile
7.19.2 Nikko Chemicals Main Business
7.19.3 Nikko Chemicals Liposomal Drug-delivery System Products, Services and Solutions
7.19.4 Nikko Chemicals Liposomal Drug-delivery System Revenue (US$ Million) & (2019-2024)
7.19.5 Nikko Chemicals Recent Developments
8 Industry Chain Analysis
8.1 Liposomal Drug-delivery System Industrial Chain
8.2 Liposomal Drug-delivery System Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Liposomal Drug-delivery System Sales Model
8.5.2 Sales Channel
8.5.3 Liposomal Drug-delivery System Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Lipoid Kosmetik
Lucas Meyer Cosmetics
Nippon Fine Chemical
Enoc Solutions
Nanovec
Lipotec
Croda
H&A Pharmachem
Lipomize
ID bio
BioSpectrum
Derma Clinical
Kewpie Corporation
Nanohealth Biotech
Creative Biostructure
Phenbiox
NOF CORPORATION
KYOWA PHARMA CHEMICAL
Nikko Chemicals
听
听
*If Applicable.
